Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coley Doubles Toll-Like Receptor Patent Estate With Purchase Of 3M Program

This article was originally published in The Pink Sheet Daily

Executive Summary

$20 million investment also gains the TLR-focused firm a pipeline of small molecule candidates targeting TLR7 and TLR8, as well as a 10,000 compound library.

You may also be interested in...



Pfizer Strengthens Therapeutic Vaccine Position With Coley Purchase

Pharma giant gains control over Coley’s Toll-like receptor patent estate and next-generation vaccine adjuvants with $164 million acquisition.

Pfizer Strengthens Therapeutic Vaccine Position With Coley Purchase

Pharma giant gains control over Coley’s Toll-like receptor patent estate and next-generation vaccine adjuvants with $164 million acquisition.

Pfizer Picks Second TRL9 Candidate From Coley For Development In Oncology

Company will continue investigating compounds despite a recent setback with its Toll-like receptor program in lung cancer.

Related Content

Topics

UsernamePublicRestriction

Register

OM016276

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel